Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health, Inc. disclosed a lease and related guaranty executed on September 1, 2025. The lease has an initial 15-year term with two successive five-year extension options and a Rent Commencement Date of April 1, 2026. The first-year annual base rent is $5,984,204 (about $498,684 per month) and will escalate ~3.25% annually. Base rent is fully abated from the Lease Commencement Date through the day before the Rent Commencement Date, and a monthly abatement of $262,838.42 applies for five months after rent begins. Hims is responsible for operating expenses starting at Rent Commencement. A $5,984,204 letter of credit from JPMorgan Chase secures Hims’ obligations, and the company filed a guaranty of the lease.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported option exercises and share sales on 08/26/2025 effected under a Rule 10b5-1 trading plan adopted May 31, 2024. The reporting person exercised 11,581 stock options with an exercise price of $5.01 per share and sold 11,581 Class A shares at an average weighted price of $43.6895 (sale prices ranged $43.55–$43.86). After these transactions, the reporting person beneficially owned 128,387 Class A shares directly and 7,853 shares indirectly via the Oluyemi Okupe Separate Property Trust dated 9-1-2021.
The exercised options increase the total number of shares underlying outstanding options to 349,784, with 11,581 options newly exercised and subject to standard vesting terms that began January 24, 2022.
Insider sale by HIMS officer: The Form 4 shows Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), sold 2,571 shares of Class A common stock on 08/25/2025 at a price of $44.53 per share. After the reported sale, Boughton beneficially owned 150,450 shares. The filing was signed by an attorney-in-fact on 08/26/2025 and indicates the sale was executed under the reporting person’s authority.
Form 144 filed relating to HIMS (HIMS): The notice reports a proposed sale of 2,571 Class A shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $114,486.63 and an approximate sale date of 08/25/2025. The shares were acquired on 06/15/2025 by Restricted Stock Vesting from the issuer and were paid as compensation. The filing lists multiple prior Class A sales by Soleil Boughton between 05/27/2025 and 08/11/2025, showing amounts and gross proceeds for each trade. Some issuer and filer identifying fields in the header are blank or not provided in the document.
Andrew Dudum, Director and CEO of Hims & Hers Health, Inc. (HIMS), reported multiple transactions on 08/18/2025 conducted under a Rule 10b5-1 plan. The filing shows option exercises at an exercise price of $2.43 for 17,001 and 108,334 options, and subsequent sales of shares from those exercises and existing holdings at average weighted prices in the mid-$44 to mid-$45 range. Reported sales on that date include blocks of 47,534; 2,792; 17,001; 41,667; 50,000; and 16,667 shares at various average prices around $44.76–$45.42. Post-transaction beneficial ownership across direct and indirect holdings is reported for numerous trusts, with notable indirect positions such as 1,016,871 and 2,214,769 shares held by trustees. The Form 4 is signed by an attorney-in-fact on 08/20/2025.
Form 144 notice for Hims & Hers Health, Inc. (HIMS) reports proposed and recent sales of Class A common stock by insiders and related parties. The filing lists a proposed sale of 47,534 shares via Fidelity (approximate market value $2,141,494) with an approximate sale date of 08/18/2025 on the NYSE. It shows acquisition details for 46,534 vested restricted shares received in 2022 and 2023 as compensation. The filing also discloses multiple completed insider sales between 06/16/2025 and 07/21/2025 totaling several hundred thousand shares and gross proceeds in the multi‑million dollar range. The filer certifies they are not aware of undisclosed material adverse information.
Form 144 notice for HIMS (Class A) shows a proposed sale of 128,127 Class A shares with an aggregate market value of $5,793,902.94, scheduled approximately for 08/18/2025. The filing reports that 125,335 of those shares derive from an option granted on 06/17/2020 and are to be sold for cash on 08/18/2025, while 2,792 shares were acquired by restricted stock vesting on 06/15/2024 as compensation. The issuer's outstanding Class A shares are reported as 217,641,958. The filing also discloses multiple Class A sales by Andrew Dudum and the Dudum Family Trust between 06/16/2025 and 07/21/2025 with detailed gross proceeds for each transaction.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported transactions on 08/13/2025. The filing shows acquisition of 11,581 shares at an exercise price of $5.01 and a contemporaneous sale of 11,581 shares at a weighted average price of $48.0459, with sales executed in the range $47.84–$48.32. The report also records a transfer of 62,722 Class A shares from the Oluyemi Okupe Separate Property Trust dated 9-1-2021 to the reporting person’s direct holdings. Post-transaction direct beneficial ownership is reported as 65,665 Class A shares. The exercised options referenced vest per a schedule beginning January 24, 2023, with full monthly vesting thereafter and expire February 23, 2032.
Andrew Dudum, Chief Executive Officer and director of Hims & Hers Health, Inc., reports beneficial ownership equal to 23,820,905 shares of Class A common stock on a fully converted/exercised basis, representing 10.3% of Class A. That total combines shares held directly and in affiliated trusts, Class V common stock that converts into Class A, restricted stock units expected to settle within 60 days, and a large block of stock options exercisable within 60 days.
The filing breaks down the holdings: 9,333,039 Class A shares held by affiliated trusts, 92,313 held directly, 8,377,623 Class V shares, 164,368 Class A shares underlying RSUs expected to settle within 60 days, 5,643,186 options exercisable within 60 days, plus additional options and RSUs subject to vesting; 1,296,568 RSUs not expected to settle within 60 days are excluded from the aggregate amount. The filing also notes that Class V shares convert into Class A upon transfer or by Board resolution after specified trigger conditions.
Capital World Investors (a division of Capital Research and Management Company and affiliated investment management entities) is reported as the beneficial owner of 18,559,302 shares of Hims & Hers Health, Inc., representing 8.6% of the approximately 215.5 million shares outstanding. CWI holds 18,553,317 shares with sole voting power and 18,559,302 shares with sole dispositive power; no shared voting or dispositive power is reported. The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control. The Growth Fund of America is identified in the filing as an account on behalf of which ownership is reported.